Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Game theory

<< Previous

Bullboard Posts

Next >>

Comment by Capitalistaon Aug 13, 2022 2:45pm

159 Views

Post# 34894185

RE:RE:RE:RE:RE:Game theory

Capitalista wrote: I agree - the BD guy didn't mention buyouts at all last Thursday. However, they were mentioned as a possibility in previous webinars. I imagine if someone through $8 to $15 billion at ONC, they would think hard about it.

My thought is that if a Big PharmaCo looks at ONC and sees it is efficacious over several different cancer types and several different types of treatment (CAR-T, combos with chemotherapeutic and immunotherapeutic agents), owning it would be far preferable to having a partnership and Phase III trial for only one application.

*threw* Ah hates typos

<< Previous

Bullboard Posts

Next >>

Changing Europe’s dependency on HREE from China